Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW PARTNERSHIP PROVIDES TRANSFORMATIVE GRANTS TO EMPOWER CONFIDENCE IRVINE, Calif. , March 8, 2023 /PRNewswire/ -- In honor of International Women's Day, Allergan Aesthetics, an AbbVie company (NYSE: ABBV) today announced that BOTOX® Cosmetic is partnering with IFundWomen, the go-to funding marketplace for women-owned businesses, on a grant program.

BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs

NORTH CHICAGO, Ill. , March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023.

AbbVie to Present at the Barclays Global Healthcare Conference

AbbVie Inc. (NYSE:ABBV ) Cowen 43rd Annual Healthcare Conference Call March 7, 2023 9:10 AM ET Company Participants Roopal Thakkar - Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer Robert Michael - Vice Chairman and President Jeffrey Stewart - Executive Vice President and Chief Commercial Officer Conference Call Participants Stephen Scala - Cowen and Company, LLC Stephen Scala [Call Starts Abruptly] Cowen conference again this year. We have four members of management.

AbbVie Inc. (ABBV) Cowen 43rd Annual Healthcare Conference (Transcript)

Apple

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Alibaba

Bank of America

BASF SE

Bayer AG

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season.

My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales

Colgate-Palmolive

Procter & Gamble

Johnson & Johnson

Coca-Cola

Northwest Natural Gas

Sysco

Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years.

7 Dividend Kings to Buy for an Uncertain Market Environment

Abbott Labs

Putting some shares of these stocks in your portfolio now could lead to heaps of passive income in your retirement years.

2 High-Yield Dividend Stocks to Buy in March

Amazon

Chevron

Alphabet

Eli Lilly

NVIDIA

PepsiCo

Tesla

After a strong performance in January, the stock market lost pace in the second month of the year.

5 Best and Worst Performing Mega-Cap Stocks in February 2023

Roche Holding AG

RHHBY vs. ABBV: Which Stock Is the Better Value Option?

Costco

Microsoft

These are dividend stocks you won't have to worry about.

Intel Slashed Its Dividend, But These 3 Yields Are Likely to Continue Rising

Realty Income Corp

They'll generate cash now, and even more cash in the future.

These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio

American Water Works

McDonald's

In today's volatile and uncertain market, investors increasingly seek stable, reliable, and resilient companies to add to their portfolios. Defensive stocks, which are typically associated with companies that operate in industries that provide essential goods and services, can provide a hedge against market downturns while still delivering consistent returns.

3 Top Defensive Stocks to Own for a Focus on Quality

Amgen

Pfizer

These three undervalued healthcare stocks are solid picks for patient investors.

3 Value Stocks You'll Regret Not Buying on the Dip

Medtronic

With a little planning, you can receive a dependable dividend payout every month.

Get a Dividend Every Month With These 3 Healthcare Stocks

Black Hills

Emerson Electric

Federal Realty Investment Trust

Leggett & Platt

Lowe's

Altria

National Fuel Gas

Universal Corp

V.F.

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive years."--Dogs of the Dow. The 47 Dividend Kings screened as of February 24, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 15.54%-31.75% topped-by NFG & VFC.

March Dividend Kings: 5 Buys, 4 To Watch

NORTH CHICAGO, Ill. , Feb. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023.

AbbVie to Present at the Cowen 43rd Annual Health Care Conference

GE HealthCare Technologies Inc

Haleon PLC

LyondellBasell Industries

AT&T

Verizon

There are two notable trades that are not buys this month as I decided to shuttle Haleon plc and GE HealthCare Technologies. Rarely does a spin-off these days equate to a solid real world standalone company.

Recent Stock Purchase/Sale February 2023

A total of 24 accepted abstracts, including six oral and digital oral presentations, reinforce AbbVie's commitment to research that helps advance standards of care for patients living with i nflammatory bowel diseases Data from ADVANCE, MOTIVATE and FORTIFY studies highlighting efficacy outcomes and clinical response in patients receiving SKYRIZI for treatment of moderately to severely active Crohn's disease Oral presentations from sub-analyses of U-EXCEL, U-EXCEED and U-ENDURE address treatment of moderately to severely active Crohn's disease, including efficacy outcomes from the upadacitinib (RINVOQ® ) clinical trial program NORTH CHICAGO, Ill. , Feb. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present further analyses on SKYRIZI® (risankizumab) in Crohn's disease (CD) and RINVOQ® (upadacitinib) in ulcerative colitis (UC) as well as the investigational use of upadacitinib in CD at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), to be held March 1-4 in Copenhagen, Denmark.

AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)

The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain5,6 If approved by the European Commission (EC), this will be the seventh indication for upadacitinib in the European Union (EU), and the first JAK inhibitor for Crohn's disease, adding to AbbVie's gastroenterology portfolio NORTH CHICAGO, Ill. , Feb. 27, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.1-4 "The recent CHMP recommendation to approve upadacitinib for use in Crohn's disease is a momentous step, bringing us closer to offering a first-of-its-kind, once-daily oral treatment that can make a difference for people living with this disease," said Roopal Thakkar, M.D.

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease

News for AbbVie Stock (ABBV)